Open Access

T‑cadherin is associated with prognosis in triple‑negative breast cancer

  • Authors:
    • De‑Di Kong
    • Mei‑Hong Wang
    • Jie Yang
    • Liang Li
    • Wei Wang
    • Shi‑Bing Wang
    • Yan‑Zhen Zhou
  • View Affiliations

  • Published online on: June 30, 2017     https://doi.org/10.3892/ol.2017.6505
  • Pages: 2975-2981
  • Copyright: © Kong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The purpose of the present study was to assess the prognostic impact of T‑cadherin expression in patients with triple‑negative breast cancer (TNBC). On the basis of the results of immunohistochemical analysis, 106 patients with operable TNBC were divided into two groups, the T‑cadherin‑positive group and T‑cadherin‑negative group. Fisher's exact and χ2 tests were employed to analyze clinical data, which included the association between T‑cadherin expression and clinicopathological features and prognosis. The log‑rank test was used to examine the impact of T‑cadherin expression on the 5‑year disease‑free survival (DFS) and the 5‑year overall survival (OS) of these patients. Kaplan‑Meier and Cox regression analyses were introduced to analyze DFS and OS. Compared with the T‑cadherin‑positive group (58.3, 52.8 and 47.2, respectively; P=0.018, P=0.017, and P=0.047), tumor size >2 cm, grade II and III (Elston‑Ellis modification of Bloom‑Richardson grading system), and positive lymph node status were significantly more common in the T‑cadherin‑negative group compared with the T‑cadherin‑positive group (80.0 vs. 58.3%, 75.7 vs. 52.8% and 67.1 vs. 47.2%, respectively) (P=0.018, P=0.017, and P=0.047). Compared with the T‑cadherin‑positive group, 5‑year DFS and OS levels were significantly lower in the T‑cadherin‑negative group (Z=6.233, P=0.013; Z=5.366, P=0.021). Multivariate analysis revealed that negative T‑cadherin expression was an independent prognostic factor for DFS (P=0.009) and OS (P=0.048). The results of the present study indicated that negative T‑cadherin expression indicated a worse prognosis for patients with TNBC.
View Figures
View References

Related Articles

Journal Cover

September-2017
Volume 14 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kong DD, Wang MH, Yang J, Li L, Wang W, Wang SB and Zhou YZ: T‑cadherin is associated with prognosis in triple‑negative breast cancer. Oncol Lett 14: 2975-2981, 2017
APA
Kong, D., Wang, M., Yang, J., Li, L., Wang, W., Wang, S., & Zhou, Y. (2017). T‑cadherin is associated with prognosis in triple‑negative breast cancer. Oncology Letters, 14, 2975-2981. https://doi.org/10.3892/ol.2017.6505
MLA
Kong, D., Wang, M., Yang, J., Li, L., Wang, W., Wang, S., Zhou, Y."T‑cadherin is associated with prognosis in triple‑negative breast cancer". Oncology Letters 14.3 (2017): 2975-2981.
Chicago
Kong, D., Wang, M., Yang, J., Li, L., Wang, W., Wang, S., Zhou, Y."T‑cadherin is associated with prognosis in triple‑negative breast cancer". Oncology Letters 14, no. 3 (2017): 2975-2981. https://doi.org/10.3892/ol.2017.6505